TABLE 2.

Sequential profiles of CSF from a compromised individual with C. albicans meningitis

Daya	Amphotericin B dose (g)b	Days of caspofungin use	CSF culture for C. albicansc	No. of RBC/mm3 of CSFe	No. of WBC/mm3 of CSFf	% S/M/Ld	CSF glucose level (mg/dl)	CSF protein level (mg/dl)
23	0		−	110,000	1,500	87/6/7	18	686
33	0		+	5,616	576	84/0/16	83	106
40	0		+	72	1,158	81/19/0	59	117
43	0.05		+	58	145	72/21/7	74	78
57	0.75		−	120	10	10/70/20	57	49
65	1.15		−	2,080	20	65/30/5	65	109
71	1.40		+	8	13	70/15/15	63	36
78	1.80		+	57	24	66/34/0	74	30
103	2.90	1	+
104	2.95	2	+	11	14	70/12/18		75
107	3.10	5
109		7	−	3,890	13	61/19/18	41	42
116		14	−	0	35	72/8/20	45	50
126		24	−	0	4	0/25/75	54	33

^aDay 0, the day chemotherapy was started; day 23, the first day a lumbar puncture was performed.

^bCumulative dose of parenteral amphotericin B. Total cumulative dose, 3.1 g.

^c+ and −, positive and negative for growth of C. albicans in CSF.

^dPercentages of segmented neutrophils (S), monocytes (M), and lymphocytes (L), respectively.

^eRBC, red blood cells.

^fWBC, white blood cells.